Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Sep 30;11(10):1815.
doi: 10.3390/diagnostics11101815.

Case Report of COVID-19 after Full Vaccination: Viral Loads and Anti-SARS-CoV-2 Antibodies

Magdalena Komiazyk  1 , Jaroslaw Walory  1 , Jan Gawor  2 , Iza Ksiazek  1 , Robert Gromadka  2 , Anna Baraniak  1
Affiliations
Case Reports

Case Report of COVID-19 after Full Vaccination: Viral Loads and Anti-SARS-CoV-2 Antibodies

Magdalena Komiazyk et al. Diagnostics (Basel). .

Abstract

The introduction of effective vaccines against SARS-CoV-2 is expected to prevent COVID-19. However, sporadic cases of infection in vaccinated persons have been reported. We describe a case of a double-dose vaccinated woman with COVID-19. All stages of infection were observed, from no identification of virus, then the start of the infection, a high viral load, coming out of viraemia, and finally no detection of the virus. Despite the high viral load, the woman demonstrated mild COVID-19 symptoms, manifested only by a sore throat. The antibody results showed that she produced both post-infectious and post-vaccination immune responses. Phylogenetic analysis of the obtained viral genome sequence indicated that the virus belonged to the UK SARS-CoV-2 lineage B.1.1.7 (GR 501Y.V1; 20I/S:501Y.V1; Alpha variant).

Keywords: COVID-19; anti-SARS-CoV-2 antibodies; mRNA vaccine; viral loads.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
The timeline of the case. (a) shows the two doses of vaccine (green arrows), the identification of COVID-19 in the husband (yellow dot), the RT-qPCR tests performed in the woman (violet dots), and the duration of COVID-19 symptoms in the woman (red line). (b) shows the levels of anti-SARS-CoV-2 antibodies: IgG-S1 (orange line), IgA-s1 (blue line), IgG-N (grey line).
Figure 2
Figure 2
Phylogenetic analysis of SARS-CoV-2 isolate. Sample EPI_ISL_1257898 is marked as red dot.
See this image and copyright information in PMC

References

    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. World Health Organization Coronavirus Disease 2019. 2020. [(accessed on 23 March 2021)]. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Yang Y., Yang M., Yuan J., Wang F., Wang Z., Li J., Zhang M., Xing L., Wei J., Peng L., et al. Laboratory diagnosis and monitoring the viral shedding of SARS-CoV-2 infection. Innovation. 2020;1:100061. - PMC - PubMed
    1. Walsh K.A., Jordan K., Clyne B., Rohde D., Drummond L., Byrne P., Ahern S., Carty P.G., O’Brien K.K., O’Murchu E., et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J. Infect. 2020;81:357–371. doi: 10.1016/j.jinf.2020.06.067. - DOI - PMC - PubMed
    1. Okba N.M., Müller M.A., Li W., Wang C., GeurtsvanKessel C.H., Corman V.M., Lamers M.M., Sikkema R.S., De Bruin E., Chandler F.D., et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg. Infect. Dis. 2020;26:1478–1488. doi: 10.3201/eid2607.200841. - DOI - PMC - PubMed

Publication types

LinkOut - more resources